logo-loader
viewDynavax Technologies

Dynavax shares skyrocket after its Hepatitis B drug gets US FDA advisory committee approval

Dynavax said should the vaccine be given the green light, it will seek a recommendation from the CDC's immunization practices advisory committee and plans a commercial launch of the vaccine in early 2018 "on its own or through a commercial partner."

injection
Dynavax shares have surged 88.11% to $17.40 in premarket trade.

Dynavax Technologies Corp. (NYSE:DVAX) shares jumped 88% in premarket trade Monday after a US Food and Drug Administration (FDA) advisory committee said the safety data for its Hepatitis B vaccination supported its approval.

The advisory committee voted 12 to 1 on the safety data, with three members abstaining.

A previous advisory committee had voted 13 to 1 in favor of the vaccine's ability to promote an immune response.

On Monday, Dynavax was upgraded to overweight at J.P. Morgan with a US$27 price target and upgraded to outperform at RBC Capital Markets with a US$26 price target.

Although there are already Hepatitis B vaccines in the market, they require three doses administered over six months, while Dynavax's HEPLISAV-B vaccine only requires two doses over a month period, the company said.

An FDA decision on the approval of the vaccine is expected by August 10.

Dynavax said should the vaccine be given the green light, it will seek a recommendation from the CDC's immunization practices advisory committee.

The company plans a commercial launch of the vaccine in early 2018 "on its own or through a commercial partner."

Dynavax shares have surged 88.11% to $17.40 in premarket trade and then later gained 76% to $16.37 each.

Quick facts: Dynavax Technologies

Price: 5.9 USD

NASDAQ:DVAX
Market: NASDAQ
Market Cap: $494.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Bulls Bears & Brokers: Martin Place Securities Barry Dawes on market highs...

Martin Place Securities executive chairman Barry Dawes speaks to Proactive about the highs and lows of the markets, and takes us through his bulls and bears outlook. Dawes says there are record highs in equity markets, bond markets are turning down again, currencies are showing trendless...

5 hours, 7 minutes ago

2 min read